Novel treatments and future perspectives: Outcomes of intrathecal drug delivery

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Intrathecal enzyme replacement therapy (ERT) holds promise as a treatment for the central nervous system manifestations of lysosomal storage diseases. Treatment via the cerebrospinal fluid represents a potential method of delivering recombinant enzyme across the blood-brain barrier. Experiments in animal models of mucopolysaccharidosis (MPS) Type I, MPS II and MPS IIIA have shown that ERT delivered via the intrathecal route distributes throughout the central nervous system and penetrates brain tissue, where it promotes clearance of lysosomal storage material. Studies are underway to investigate the safety and efficacy of intrathecal ERT in patients with MPS I.

Original languageEnglish
Pages (from-to)S124-S127
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Issue numberSUPPL. 1
StatePublished - Dec 1 2009


  • Animal models
  • Blood-brain barrier
  • Enzyme replacement therapy
  • Intrathecal
  • Lysosomal storage disease
  • Mucopolysaccharidoses


Dive into the research topics of 'Novel treatments and future perspectives: Outcomes of intrathecal drug delivery'. Together they form a unique fingerprint.

Cite this